Skip to content
Screener

Common Stock at other companies

Eli Lilly logo
Eli LillyLLY
$588M-0.7%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$3.12B
Amgen logo
AmgenAMGN
2.8B0.0%
CTO
Citius Oncology, Inc.CTOR
400M+300%
Vor Biopharma logo
Vor BiopharmaVOR
$19K+46.2%
Climb Bio, Inc. logo
Climb Bio, Inc.CLYM
$5K-28.6%

Other financials

Income statement

See full
Revenue-
Operating income-$57.3M+24.5%
Net income-$53.7M+23.3%
EPS (diluted)-$0.69+24.2%

Balance sheet

See full
Cash & equivalents$78.6M+8.0%
Total debt$2.1M+36.3%
Total equity$408.7M-30.8%
Total assets$363.8M-30.1%

Cash flow

See full
Operating cash flow-$38.2M+33.7%
CapEx$11.0K
Free cash flow-$38.1M-4.1%

Valuation

See full
Market cap$1.16B+148%
Enterprise value$1.08B+174%

Profitability

See full
Operating margin-358.7%
Net margin-346.1%

Returns & leverage

See full
Return on equity-44%+26.2pp
Debt / equity0.0×
Current ratio8.4×-1.4×

Where this comes from

Reported directly by Cullinan Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The source filing: Cullinan Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:10 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336717
Line itemJune 30, 2026December 31, 2025
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 204,209 and 555,935 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively.
Common stock, $0.0001 par value, 150,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 64,345,770 and 60,244,136 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively66
Additional paid-in capital1,013,366995,823
Accumulated other comprehensive income (loss)(134)1,020
Accumulated deficit(691,484)(588,119)
Total stockholders' equity321,754408,730

Item 1. Financial Statements.

FAQ

What is Cullinan Therapeutics, Inc.'s common stock?
Cullinan Therapeutics, Inc. (CGEM) reported common stock of $6K in Q2 2026.
How has Cullinan Therapeutics, Inc.'s common stock changed year-over-year?
Cullinan Therapeutics, Inc.'s common stock decreased by 0.0% year-over-year, from $6K to $6K.
What is the long-term trend for Cullinan Therapeutics, Inc.'s common stock?
Over 5 years (2020 to 2025), Cullinan Therapeutics, Inc.'s common stock has grown at a 14.9% compound annual growth rate (CAGR), from $3K to $6K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about Cullinan Therapeutics, Inc.'s common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude